These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 2103559)

  • 1. [Diagnosis, prevention and treatment of renal and urinary tract lithiasis].
    Tamayo JA; Peña JC
    Gac Med Mex; 1990; 126(6):497-505; discussion 505-7. PubMed ID: 2103559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy.
    Pak CY; Sakhaee K; Fuller CJ
    Trans Assoc Am Physicians; 1983; 96():294-305. PubMed ID: 6679957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic abnormalities associated with calyceal diverticular stones.
    Auge BK; Maloney ME; Mathias BJ; Pietrow PK; Preminger GM
    BJU Int; 2006 May; 97(5):1053-6. PubMed ID: 16643491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Functional evaluation in patients with kidney calculi].
    Stojimirović B
    Srp Arh Celok Lek; 1998; 126(9-10):394-8. PubMed ID: 9863414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate).
    Conte A; Pizá P; García-Raja A; Grases F; Costa-Bauzá A; Prieto RM
    Arch Esp Urol; 1999 Apr; 52(3):305-10. PubMed ID: 10371752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Jejunoileal bypass reversal: effect on renal function, metabolic parameters and stone formation.
    Dhar NB; Grundfest S; Jones JS; Streem SB
    J Urol; 2005 Nov; 174(5):1844-6; discussion 1846. PubMed ID: 16217311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate).
    Conte A; Pizá P; García-Raja A
    Arch Esp Urol; 1999; 52(1):94-9. PubMed ID: 10101897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of renal stone risk by potassium-magnesium citrate during 5 weeks of bed rest.
    Zerwekh JE; Odvina CV; Wuermser LA; Pak CY
    J Urol; 2007 Jun; 177(6):2179-84. PubMed ID: 17509313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of hyperuricosuric calcium oxalate nephrolithiasis with potassium citrate.
    Pak CY; Peterson R
    Arch Intern Med; 1986 May; 146(5):863-7. PubMed ID: 3963975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of citrate on the different phases of calcium oxalate crystallization.
    Tiselius HG; Berg C; Fornander AM; Nilsson MA
    Scanning Microsc; 1993 Mar; 7(1):381-9; discussion 389-90. PubMed ID: 8316807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetazolamide is an effective adjunct for urinary alkalization in patients with uric acid and cystine stone formation recalcitrant to potassium citrate.
    Sterrett SP; Penniston KL; Wolf JS; Nakada SY
    Urology; 2008 Aug; 72(2):278-81. PubMed ID: 18533229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alkaline citrate in prevention of recurrent calcium oxalate stones.
    Berg C
    Scand J Urol Nephrol Suppl; 1990; 130():1-83. PubMed ID: 2291093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ionized calcium and cyclic AMP in plasma and urine. Biochemical evaluation in calcium metabolic disease.
    Thode J
    Scand J Clin Lab Invest Suppl; 1990; 197():1-45. PubMed ID: 2154030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A study on the cause of urolithiasis of the upper urinary tract--clinical study of risk factors in the formation of stones in the upper urinary tract].
    Nonomura M; Kawamura J; Ueda M; Okada Y; Takeuchi H; Yoshida O
    Hinyokika Kiyo; 1986 Mar; 32(3):311-25. PubMed ID: 3728237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of potassium and magnesium supplementations on urinary risk factors of renal stone patients.
    Jaipakdee S; Prasongwatana V; Premgamone A; Reungjui S; Tosukhowong P; Tungsanga K; Suwantrai S; Noppawinyoowong C; Maskasame S; Sriboonlue P
    J Med Assoc Thai; 2004 Mar; 87(3):255-63. PubMed ID: 15117041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experimental and clinical studies on calcium lithiasis. II. Prevention of recurrent calcium stones with thiazides and allopurinol].
    Okada Y; Nonomura M; Takeuchi H; Kawamura J; Yoshida O
    Hinyokika Kiyo; 1986 Sep; 32(9):1247-57. PubMed ID: 3812144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current status of prevention and therapy of urinary calculi and peroral chemo-litholysis with special attention to the relationship of increased excretion of uric acid in oxalate lithiasis].
    Leskovar P
    Z Urol Nephrol; 1980 Mar; 73(3):229-39. PubMed ID: 7434987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body size and 24-hour urine composition.
    Taylor EN; Curhan GC
    Am J Kidney Dis; 2006 Dec; 48(6):905-15. PubMed ID: 17162145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of factors involved in calcium stone formation.
    Abraham PA; Smith CL
    Miner Electrolyte Metab; 1987; 13(3):201-8. PubMed ID: 3627051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.